Becker's Healthcare November 19, 2024
In an unconventional push to expand coverage for weight loss medications, Eli Lilly representatives recently visited the New Jersey State Policemen’s Benevolent Association to promote their drug Zepbound with a goal to convince that organization of the long-term cost savings associated with obesity treatment, The Wall Street Journal reported Nov. 19.
Drugmakers are likewise reaching out to other employers with the message that treating obesity will ultimately save them money.
Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy, both priced at over $1,000 a month, have faced resistance from employers due to their...
Today's Sponsors
Today's Sponsor